Lannion,
2020 first-half revenues (erratum1)
Consolidated revenues (unaudited)
Revenues (€m) | 2020 | 2019 | reported change | organic change | pro forma 2020 2 |
First quarter | 21.9 | 24.2 | -9.4% | -17.2% | |
Second quarter | 24.3 | 27.5 | -11.7% | -17.1% | |
First half | 46.2 | 51.7 | -10.6% | -17.4% | 65.0 |
of which | |||||
Laser | 30.4 | 34.0 | -10.7% | -18.0% | 30.4 |
Medical | 15.8 | 17.7 | -10.5% | -16.2% | 34.6 |
1 Organic change: at constant exchange rates and like-for-like
2 Including Ellex at
The Lumibird Group’s consolidated revenues came to €46.2m for the first half of 2020, down 10.6%. Like-for-like and at constant exchange rates, taking into account the acquisitions of Optotek Medical and Halo Photonics, this contraction comes to -17.4%. Including Ellex’s laser and ultrasound activities at
Following a first quarter marked by reduced operational schedules for the Defense / Space contracts,
Within the Laser division, the Defense / Space business (-27.2% to €8.6m) is still subject to less active schedules for operations than one year ago, as expected, on its longstanding contracts, as well as new contracts that are still starting up. The Industrial and Scientific business (-8.0% to €12.3m) saw its contraction pick up pace slightly during the second quarter due to the closure of a certain number of research laboratories and universities. However, the Lidar business recorded growth (+7.2% to €9.4m) thanks to the inclusion of Halo Photonics in the scope and to deliveries on large contracts to US integrators.
The Medical division (-10.5% to €15.8m) was affected by the crisis during the second quarter due to the cancellation of major European ophthalmology conferences, which have historically been key periods for commercial activity. The commercial policy has been adapted to the context for distance selling, with orders deferred over time. Elsewhere, the significant impact of the crisis in
The new combined structure, Lumibird Medical, is a world leader for laser and ultrasound technologies for the diagnosis and treatment of ocular diseases, with revenues of around €80m (2019 pro forma revenues). The commercial brands
Today, the Group has considerably strengthened the position of its Medical division, which is still one of its three core strategic markets, alongside the Lidar and Defense / Space markets.
In terms of results, the efforts made to reduce expenses should offset the decline in sales over the first half period.
Next date: H1 2020 results on
Born from the combination of
Contacts
Chairman and CEO Tel. +33(0) 1 69 29 17 00 info@lumibird.com | Aude Nomblot-Gourhand Secretary General – CFO Tel. +33(0) 1 69 29 17 00 info@lumibird.com | Calyptus Investors Relations Tel. +33(1) 53 65 37 91 lumibird@calyptus.net |
1 corrections highlighted in yellow
Attachment
- 200727LumibirdCAS12020EN_erratum
© OMX, source